Drug intelligence / Profile preview

LIPG siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
In Vitro
01

Overview

LIPG siRNA is an experimental small interfering RNA designed to silence the expression of the *LIPG* gene, which encodes endothelial lipase. In preclinical studies of uterine corpus endometrial carcinoma (UCEC), LIPG has been identified as a critical hub gene that promotes tumor cell proliferation and migration while modulating the immune microenvironment. By utilizing the RNA interference (RNAi) pathway, LIPG siRNA targets and degrades LIPG mRNA, thereby reducing the protein's expression and inhibiting its pro-oncogenic effects. This agent is currently used as a research tool to investigate lipid metabolism's role in cancer progression and as a potential therapeutic strategy.

Other names
si-LIPGsmall interfering RNA targeting LIPGLIPG-siRNA
02

Targets

LIPG (Endothelial lipase)

Beyond the preview

Go deeper on LIPG siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIPG siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call